The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33781518/
CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T cell therapy is associated with early toxicities, including cytokine release syndrome and neurotoxicity. The incidence and severity o ...
-
Mark FeslerApril 07, 2021Given that carTs often cancel higher risk subsets of disease, such as double hit genetics, it’s surprising that a simple clinical risk score would be predictive of outcome ....